The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Open accessAbstract
Purpose: AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of chemopotentiation in p53-deficient tumors in preclinical models. In a phase I study, the maximum tolerated dose of AZD1775 in combination with carboplatin demonstrated target engagement. We conducted a proof-of-principle phase II study in patients with p53 tumor suppressor gene ( TP53)–mutated ovarian cancer refractory or resistant (< 3 months) to first-line platinum-based therapy to determine overall response rate, progression-free and overall survival, pharmacokinetics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies. Patients and Methods: Patients were treated with carboplatin (area under the curve, 5 mg/mL⋅min) combined with AZD1775 225 mg orally twice daily over 2.5 days every 21-day cycle until disease progression. Results: AZD1775 plus carboplatin demonstrated manageable toxicity; fatigue (87%), nausea (78%), thrombocytopenia (70%), diarrhea (70%), and vomiting (48%) were the most common adverse events. The most frequent grade 3 or 4 adverse events were thrombocytopenia (48%) and neutropenia (37%). Of 24 patients enrolled, 21 patients were evaluable for efficacy end points. The overall response rate was 43% (95% CI, 22% to 66%), including one patient (5%) with a prolonged complete response. Median progression-free and overall survival times were 5.3 months (95% CI, 2.3 to 9.0 months) and 12.6 months (95% CI, 4.9 to 19.7), respectively, with two patients with ongoing response for more than 31 and 42 months at data cutoff. Conclusion: To our knowledge, this is the first report providing clinical proof that AZD1775 enhances carboplatin efficacy in TP53-mutated tumors. The encouraging antitumor activity observed in patients with TP53-mutated ovarian cancer who were refractory or resistant (< 3 months) to first-line therapy warrants further development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M., & Dalla-Favera, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.12.5413 · Cited by 885
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Rustin, G. J. S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G., Jakobsen, A., Sagae, S., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182070f17 · Cited by 625
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15.
McGowan, C. H., & Russell, P. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05633.x · Cited by 493
Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle.
Watanabe, N., Broome, M., & Hunter, T. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07180.x · Cited by 450
Gordon, A. N., Tonda, M., Sun, S., & Rackoff, W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.011 · Cited by 422
Do, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., & Kummar, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4009 · Cited by 322
Self-citationRajeshkumar, N. V., De Oliveira, E., Ottenhof, N., Watters, J., Brooks, D., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274
Wee1 kinase as a target for cancer therapy
Do, K., Doroshow, J. H., & Kummar, S. (2013) · Cell Cycle · doi:10.4161/cc.26062 · Cited by 273
Berchuck, A., Iversen, E. S., Lancaster, J. M., Pittman, J., Luo, J., Lee, P., Murphy, S., Dressman, H. K., Febbo, P. G., West, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2398 · Cited by 266
Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11115 · Cited by 237
Markman, M., Blessing, J., Rubin, S. C., Connor, J., Hanjani, P., & Waggoner, S. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.10.036 · Cited by 237
Poveda, A. M., Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1408 · Cited by 232
Knockdown of Chk1, Wee1 and Myt1 by RNA Interference Abrogates G2 Checkpoint and Induces Apoptosis
Wang, Y., Decker, S. J., & Sebolt, J. S. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.3.697 · Cited by 155
Structure and Inhibition of the Human Cell Cycle Checkpoint Kinase, Wee1A Kinase
Squire, C. J., Dickson, J. M. J. J., Ivanović, I., & Baker, E. N. (2005) · Structure · doi:10.1016/j.str.2004.12.017 · Cited by 105
Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma
LEITAO, M., Soslow, R. A., Baergen, R. N., Olvera, N., ARROYO, C., & Boyd, J. A. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.01.043 · Cited by 88
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
van der Burg, M. E. L., de Wit, R., van Putten, W. L. J., Logmans, A., Kruit, W. H. J., Stoter, G., & Verweij, J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600002 · Cited by 87
Guertin, A. D., Martin, M. M., Roberts, B. S., Hurd, M. S., Qu, X., Miselis, N. R., Liu, Y., Li, J., Feldman, I., Benita, Y., et al. (2012) · Cancer Cell International · doi:10.1186/1475-2867-12-45 · Cited by 87
Hagopian, G. S., Mills, G. B., Khokhar, A. R., Bast, R. C., & Siddik, Z. H. (1999) · PubMed · Cited by 78
Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
Monk, B. J., & Coleman, R. L. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181c104fa · Cited by 65
Sharma, R., Graham, J., Mitchell, H., Brooks, A., Blagden, S. P., & Gabra, H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604914 · Cited by 65
Expression signatures of TP53 mutations in serous ovarian cancers
Bernardini, M. Q., Baba, T., Lee, P. S., Barnett, J. C., Sfakianos, G. P., Secord, A. A., Murphy, S. K., Iversen, E. S., Marks, J. R., & Berchuck, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-237 · Cited by 55
Analytical Validation of AmpliChip p53 Research Test for Archival Human Ovarian FFPE Sections
Marton, M. J., McNamara, A. R., Nikoloff, D. M., Nakao, A., & Cheng, J. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131497 · Cited by 4
Cited by
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
Tamborero, D., Rubio-Perez, C., Deu-Pons, J., Schroeder, M. P., Vivancos, A., Rovira, A., Tusquets, I., Albanell, J., Rodon, J., Tabernero, J., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0531-8 · Cited by 519
Metadata
- Authors
- Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E., Rose, S., Lee, M. A., Freshwater, T., Beijnen, J. H., & Schellens, J. H. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-12-20
- Volume
- 34
- Issue
- 36
- Pages
- 4354-4361
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2547988452
- Cited by
- 338
- References
- 26
- FWCI
- 23.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.